In 24 nivolumab-treated NSCLC patients, Nicolazzo et al. found that the presence of PD-L1+ CTCs at baseline, 3 months and 6 months post-treatment correlated with poor outcomes and disease progression [110]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.